Serum digoxin in HF is correlated with survival

Among 3782 patients with HF receiving digoxin or placebo in the DIG trial, there was a significant association between SDC and all-cause mortality. Compared with placebo, survival was significantly better for patients with SDC 0.5 to 0.8 ng/mL, and significantly worse for patients with SDC ≥1.2 ng/mL.